Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Reaches New 12-Month High – Time to Buy?

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) hit a new 52-week high on Wednesday . The stock traded as high as $42.2150 and last traded at $41.32, with a volume of 200 shares. The stock had previously closed at $36.5850.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BIOVF. Danske downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, February 19th. BNP Paribas Exane raised Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Up 12.9%

The firm has a market capitalization of $14.71 billion, a P/E ratio of 317.87 and a beta of 0.36. The firm’s 50 day moving average is $36.61 and its two-hundred day moving average is $34.06. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.90 and a quick ratio of 0.59.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $846.23 million during the quarter, compared to analysts’ expectations of $879.40 million. Swedish Orphan Biovitrum had a net margin of 1.43% and a return on equity of 15.74%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.